NCT03519997View on ClinicalTrials.gov

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

April 21, 2023

Study Completion Date

April 1, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Pembrolizumab

Pembroluzumab 200mg IV once every 3 weeks

DRUG

Bavituximab

Bavituximab 3mg/kg IV weekly

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

David Hsieh

OTHER

NCT03519997 - A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter